LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

Twist Bioscience Corp

Закрыт

СекторЗдравоохранение

26.16 3.6

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

25.79

Макс.

28

Ключевые показатели

By Trading Economics

Доход

60M

20M

Продажи

3M

99M

Прибыль на акцию

-0.45

Рентабельность продаж

21.227

Сотрудники

923

EBITDA

-2.3M

-26M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+45.76% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-272M

1.6B

Предыдущая цена открытия

22.56

Предыдущая цена закрытия

26.16

Новостные настроения

By Acuity

50%

50%

182 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

Twist Bioscience Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

20 нояб. 2025 г., 23:07 UTC

Обсуждения рынка

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 нояб. 2025 г., 22:22 UTC

Обсуждения рынка

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 нояб. 2025 г., 22:08 UTC

Обсуждения рынка

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 нояб. 2025 г., 21:57 UTC

Отчет

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 нояб. 2025 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Tech, Media & Telecom Roundup: Market Talk

20 нояб. 2025 г., 21:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

20 нояб. 2025 г., 21:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Health Care Roundup: Market Talk

20 нояб. 2025 г., 21:50 UTC

Обсуждения рынка
Отчет

Financial Services Roundup: Market Talk

20 нояб. 2025 г., 21:31 UTC

Отчет

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 нояб. 2025 г., 21:23 UTC

Отчет
Приобретения, слияния, поглощения

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 нояб. 2025 г., 21:07 UTC

Отчет

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 нояб. 2025 г., 21:06 UTC

Отчет

Webull 3Q Rev $156.9M >BULL

20 нояб. 2025 г., 21:06 UTC

Отчет

Webull 3Q EPS 7c >BULL

20 нояб. 2025 г., 21:05 UTC

Отчет

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 нояб. 2025 г., 21:04 UTC

Отчет

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 нояб. 2025 г., 21:04 UTC

Отчет

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 нояб. 2025 г., 21:04 UTC

Отчет

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit 1Q Consumer Rev $894M

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Backs FY26 Guidance

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 нояб. 2025 г., 21:00 UTC

Отчет

Intuit 1Q Global Business Solutions Rev $3B

Сравнение c конкурентами

Изменение цены

Twist Bioscience Corp Прогноз

Целевая цена

By TipRanks

45.76% рост

Прогноз на 12 месяцев

Средняя 38 USD  45.76%

Максимум 42 USD

Минимум 32 USD

Основано на мнении 5 аналитиков Wall Street, спрогнозировавших целевые цены для Twist Bioscience Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

5 ratings

5

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

31.56 / 38.6884Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Bearish Evidence

Долгосрочная

Bearish Evidence

Настроения

By Acuity

182 / 374Рейтинг в Здравоохранение

Новостные настроения

Neutral

Волатильность

Ниже среднего

Объем новостей (RCV)

Средняя

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat